Cardiac Gene Therapy with SERCA2a: from Bench to Bedside

Overview

Journal J Mol Cell Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Nov 25

PMID 21093451

Citations 28

Authors

Judith K Gwathmey

Alexan I Yerevanian

Roger J Hajjar

Affiliations

Soon will be listed here.

Abstract

While progress in conventional treatments is making steady and incremental gains to reduce mortality associated with heart failure, there remains a need to explore potentially new therapeutic approaches. Heart failure induced by different etiologies such as coronary artery disease, hypertension, diabetes, infection, or inflammation results generally in calcium cycling dysregulation at the myocyte level. Recent advances in understanding of the molecular basis of these calcium cycling abnormalities, together with the evolution of increasingly efficient gene transfer technology, have placed heart failure within reach of gene-based therapy. Furthermore, the recent successful completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium pump (SERCA2a) ushers in a new era for gene therapy for the treatment of heart failure. This article is part of a Special Section entitled "Special Section: Cardiovascular Gene Therapy".

Citing Articles

Selective SERCA2a activator as a candidate for chronic heart failure therapy.

Arici M, Hsu S, Ferrandi M, Barassi P, Ronchi C, Torre E J Transl Med. 2024; 22(1):77.

PMID: 38243248 PMC: 10797746. DOI: 10.1186/s12967-024-04874-9.

The role and mechanisms of microvascular damage in the ischemic myocardium.

Zhao B, Ruze A, Zhao L, Li Q, Tang J, Xiefukaiti N Cell Mol Life Sci. 2023; 80(11):341.

PMID: 37898977 PMC: 11073328. DOI: 10.1007/s00018-023-04998-z.

Muscle-specific sirtuin 3 overexpression does not attenuate the pathological effects of high-fat/high-sucrose feeding but does enhance cardiac SERCA2a activity.

Oldfield C, Moffatt T, OHara K, Xiang B, Dolinsky V, Duhamel T Physiol Rep. 2021; 9(16):e14961.

PMID: 34405591 PMC: 8371348. DOI: 10.14814/phy2.14961.

Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies.

Ramos-Kuri M, Meka S, Salamanca-Buentello F, Hajjar R, Lipskaia L, Chemaly E Biol Res. 2021; 54(1):23.

PMID: 34344467 PMC: 8330049. DOI: 10.1186/s40659-021-00342-6.

Calcium and Heart Failure: How Did We Get Here and Where Are We Going?.

Siri-Angkul N, Dadfar B, Jaleel R, Naushad J, Parambathazhath J, Doye A Int J Mol Sci. 2021; 22(14).

PMID: 34299010 PMC: 8306046. DOI: 10.3390/ijms22147392.

References

Ferrari F, Samulski T, Shenk T, Samulski R . Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996; 70(5):3227-34. PMC: 190186. DOI: 10.1128/JVI.70.5.3227-3234.1996. View

Monte F, Dalal R, Tabchy A, Couget J, Bloch K, Peterson R . Transcriptional changes following restoration of SERCA2a levels in failing rat hearts. FASEB J. 2004; 18(12):1474-6. DOI: 10.1096/fj.04-1714fje. View

Flotte T . Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res. 2005; 58(6):1143-7. DOI: 10.1203/01.pdr.0000189226.03684.fe. View

Donahue J, Kikkawa K, Thomas A, Marban E, LAWRENCE J . Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther. 1998; 5(5):630-4. DOI: 10.1038/sj.gt.3300649. View

Mingozzi F, Maus M, Hui D, Sabatino D, Murphy S, Rasko J . CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007; 13(4):419-22. DOI: 10.1038/nm1549. View

Galimi F, Noll M, Kanazawa Y, Lax T, Chen C, Grompe M . Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood. 2002; 100(8):2732-6. DOI: 10.1182/blood-2002-04-1245. View

Baker D, Hashimoto K, GRUPP I, Ji Y, Reed T, Loukianov E . Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res. 1998; 83(12):1205-14. DOI: 10.1161/01.res.83.12.1205. View

Hasenfuss G, Pieske B . Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002; 34(8):951-69. DOI: 10.1006/jmcc.2002.2037. View

Prunier F, Kawase Y, Gianni D, Scapin C, Danik S, Ellinor P . Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation. 2008; 118(6):614-24. DOI: 10.1161/CIRCULATIONAHA.108.770883. View

10.

Gwathmey J, Copelas L, Mackinnon R, Schoen F, Feldman M, Grossman W . Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987; 61(1):70-6. DOI: 10.1161/01.res.61.1.70. View

11.

Halbert C, Miller A, McNamara S, Emerson J, Gibson R, Ramsey B . Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther. 2006; 17(4):440-7. PMC: 4292890. DOI: 10.1089/hum.2006.17.440. View

12.

Calcedo R, Vandenberghe L, Gao G, Lin J, Wilson J . Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009; 199(3):381-90. PMC: 10826927. DOI: 10.1086/595830. View

13.

Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias E . Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007; 293(1):H762-9. DOI: 10.1152/ajpheart.00104.2007. View

14.

Periasamy M, Reed T, Liu L, Ji Y, Loukianov E, Paul R . Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J Biol Chem. 1999; 274(4):2556-62. DOI: 10.1074/jbc.274.4.2556. View

15.

Kawase Y, Ly H, Prunier F, Lebeche D, Shi Y, Jin H . Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008; 51(11):1112-9. DOI: 10.1016/j.jacc.2007.12.014. View

16.

Bridges C, Gopal K, Holt D, Yarnall C, Cole S, Anderson R . Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg. 2005; 130(5):1364. DOI: 10.1016/j.jtcvs.2005.07.035. View

17.

Kay M, Glorioso J, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001; 7(1):33-40. DOI: 10.1038/83324. View

18.

Beuckelmann D, Nabauer M, Erdmann E . Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992; 85(3):1046-55. DOI: 10.1161/01.cir.85.3.1046. View

19.

Pacak C, Mah C, Thattaliyath B, Conlon T, Lewis M, Cloutier D . Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006; 99(4):e3-9. DOI: 10.1161/01.RES.0000237661.18885.f6. View

20.

Most P, Pleger S, Volkers M, Heidt B, Boerries M, Weichenhan D . Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004; 114(11):1550-63. PMC: 529280. DOI: 10.1172/JCI21454. View